Infantile hepatic hemangioma can be associated to consumptive hypothyroidism due to overexpression of type 3 deiodinase in the endothelium of vascular tumor, which catalyzes the conversion of T4 to reverse T3 (rT3) and of T3 to T2, both of which are biologically inactive. Here, we report an infant with a massive biopsy-proven infantile hepatic hemangioma who developed thyroid dysfunction without a typical biochemical profile consistent with severe consumptive hypothyroidism, despite the large tumor burden. Our patient was treated with propranolol that rapidly resolved both hepatic hemangioma and thyroid dysfunction. We propose propranolol as a first-line therapy of thyroid dysfunction associated with infantile hepatic hemangioma, in order to avoid interference with neurological development caused by hypothyroidism in the first months of life.

Keywords:
Propranolol, Hepatic hemangioma, Thyroid dysfunction, Iodothyronine deiodinase, TSH-like factor
1.
Christinson-Lagay ER, Burrows PE, Alomari A, Dubois J, Kozakewich HP, Lane TS, Paltiel HJ, Klement G, Mulliken JB, Fishman SJ: Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J Ped Surg 2007;42:62–68.
2.
Bessho K, Etani Y, Ichirimori H, Namba N, Yoneda A, Ooue T, Chihara T, Morii E, Aoki T, Murakami M, Mushiake S, Ozono K: Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism. Eur J Pediatr 2010;169:215–221.
3.
Guven A, Aygun C, Ince H, Aydin M, Pinarli FG, Baysal K, Küçüködük S: Severe hypothyroidism caused by hepatic hemangioendothelioma in an infant of a diabetic mother. Horm Res 2005;63:86–89.
4.
Huang SA, Tu HM, Harney JW, Venihaki MB, Atul J, Kozakewich HPW, Fishman S, Larsen PR: Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000;343:185–189.
5.
Kalpatthi R, Germak J, Mizelle K, Yeager N: Thyroid abnormalities in infantile hepatic hemangioendothelioma. Pediatr Blood Cancer 2007;49:1021–1024.
6.
Mouat F, Evans HM, Cutfield WS, Hofman PL, Jefferies C: Massive hepatic hemangioendothelioma and consumptive hypothyroidism. J Pediatr Endocrinol Metab 2008;21:701–703.
7.
Laforgia N, Milano A, De Leo E, Bonifazi E: Emangioma e propanololo: considerazioni di fine trattamento. Differenze dai corticosteroidi. Eur J Pediat Dermatol 2009;19:175–191.
8.
Deb G, Donfrancesco A, Ilari I, De Sio L, Milano GM, Ghitti C, Fontana G, Sandri A, Helson L: Hemangioendothelioma: successful therapy with interferon-α. Med Pediatr Oncol 2002;38:118–119.
9.
Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A: Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649–2651.
10.
Barnés CM, Huang S, Kaipainen A, Sanoudou D, Chen EJ, Eichler GS, Guo Y, Yu Y, Ingber DE, Mulliken JB, Beggs AH, Folkman J, Fishman SJ: Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci USA 2005;102:19097–19102.
11.
Ayling RM, Davenport M, Hadzic N, Metcalfe R, Buchanan CR, Howard ER, Mieli-Vergani G: Hepatic hemangioendothelioma associated with production of humoral thyrotropin-like factor. J Pediatr 2001;138:932–935.
12.
Imteyaz H, Karnsakul W, Levine MA, Burrows PE, Benson J, Hsu S, Schwarz KB: Unusual case of hypothyroidism in an infant with hepatic hemangioma. J Pediatr Gastroenterol Nutr 2012;54:692–695.
13.
Sommers Smith SK, Smith DM: Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002;38:298–304.
14.
Truong MT, Chang KW, Berk DR, Heerema-McKenney A, Bruckner AL: Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma. J Pediatr 2010;156:335–338.
15.
Iaccarino G, Ciccarelli M, Sorriento D, Galasso G, Campanile A, Santulli G, Cipolletta E, Cerullo V, Cimini V, Altobelli GG, Piscione F, Priante O, Pastore L, Chiariello M, Salvatore F, Koch WJ, Trimarco B: Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor overexpression: a novel role for the endothelial adrenergic system. Circ Res 2005;97:1182–1189.
16.
Marsciani A, Pericoli R, Alaggio R, Brisigotti M, Vergine G: Massive response of severe infantile hepatic hemangioma to propranolol. Pediatr Blood Cancer 2010;54:176.
17.
Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, Ammour A, Broue P, Vial J, Ohanessian G, Léauté-Labrèze C, Labenne M, Vabres P, Rössler J, Bodemer C: Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr 2010;157:340–342.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.